BioNTech SE - ADR

NASDAQ:BNTX   3:59:51 PM EDT
372.39
+17.14 (+4.82%)
4:36:21 PM EDT: $372.49 +0.10 (+0.03%)
Products

Pfizer And BioNtech Announce Submission Of Initial Data To U.S. FDA To Support Booster Dose Of Covid-19 Vaccine

Published: 08/16/2021 15:42 GMT
BioNTech SE - ADR (BNTX) - :pfizer and Biontech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of Covid-19 Vaccine.
Pfizer - Phase 1 Safety, Immunogenicity Data in Individuals Who Got a Third Dose of Pfizer-biontech Vaccine Show Favorable Safety Profile, Robust Immune Responses.
Pfizer - a Booster Dose Given Within 6 to 12 Months After Primary Vaccination Schedule May Help Maintain a High Level of Protection Against Covid-19.
Pfizer Inc - After Booster Dose, Neutralizing Titers for Variants Were Similar to Wild-type.
Pfizer - Phase 1 Data Will Be Submitted to European Medicines Agency and Other Regulatory Authorities in Coming Weeks.
Pfizer - a Booster Vaccine Could Help Reduce Infection and Disease Rates in People Who Have Previously Been Vaccinated.
Pfizer Inc - Participants Received a 30-Μg Booster Dose of Bnt162b2 8 to 9 Months After Receiving Second Dose.
Pfizer Inc - Phase 3 Results Evaluating Third Dose Are Expected Shortly and Will Be Submitted to FDA, Ema and Other Regulatory Authorities Worldwide.
Pfizer Inc - Phase 3 Results Evaluating Third Dose Are Expected Shortly and Will Be Submitted to FDA, Ema and Other Regulatory Authorities Worldwide.